Refractory Anaplastic Large Cell Lymphoma

12 clinical trials · Condition

Sort:Newest first Oldest first

◉ Watch Refractory Anaplastic Large Cell Lymphoma

Record	Firm	Date
Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas (NCT04074746)	M.D. Anderson Cancer Center	2020-07-18
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas (NCT03598998)	City of Hope Medical Center	2019-02-04
Study of Pembrolizumab (MK-3475) in Combination With Romidepsin (NCT03278782)	M.D. Anderson Cancer Center	2017-11-14
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers (NCT02978625)	National Cancer Institute (NCI)	2017-09-27
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (NCT03075553)	Mayo Clinic	2017-05-17
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (NCT03017820)	Mayo Clinic	2017-04-04
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency (NCT01787409)	Mayo Clinic	2013-03-06
Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma (NCT01590732)	M.D. Anderson Cancer Center	2012-10-29
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma (NCT00939770)	Children's Oncology Group	2009-09-21

Track Refractory Anaplastic Large Cell Lymphoma automatically

Every clearance here is in the API, with alerts when new ones post.